Some modules are disabled because cookies are declined. Accept cookies to experience the full functionality of this page.
ACCEPT COOKIES
Contact
photo:EASL Press Office
EASL Press Office
+44 20 7331 5345
Share this release
Latest news
London,
11
April
2014

Immunotherapy could help tackle tough Liver Cancers

***INNOVATION IN SCIENCE***

London, England, Friday 11 April 2014 Significant new data1 presented today at the International Liver Congress™ 2014 indicate that liver cancer(Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy.

This new therapeutic approach in the treatment of HCC could be very important as without treatment the 5 yearsurvival rate is just 5%. Globally, HCC accounts for 746,000 deaths, and in the UK alone is responsible for over 4,000 deaths per year.2,3

Glypican-3 (GPC3) is a tumour associated antigen expressed in up to 70% of HCC but not in healthy humantissue. Isolating GPC3-specific T-cell receptors and expressing them on patient’s T-cells can help treat HCC, asthese T cells can recognise and eliminate GPC3-postive HCC.

The study detected and expanded MHC-multimer-positive CD8+ T-cells specific for targeted GPC3 epitopes andgrew T-cell clones. From these clones, the most specific and active T-cell receptor was isolated. When this Tcellreceptor was expressed on donor T cells it conferred specificity for GPC3, the HCC-associated antigen.Thus, it enables HLA-A2+ patient’s T cells to specifically kill GPC3+ HCC.

Systemic treatments for advanced stage HCC are constantly evolving and current approaches include drugtreatment with sorafenib - yet the current standard of care still does not offer a strong enough prognosis for patients. Liver transplant is an option for only 10 -15% of HCC carriers diagnosed at an early stage4 andtherefore the importance of other treatment options for patients is critical. This is a treatment gap that adoptive T-cell therapy could potentially fill.

Disclaimer: the data referenced in this alert is based on the submitted abstract. More recent data may bepresented at the International Liver Congress™ 2014.

- Ends -

Notes to Editors

About EASL

EASL is the leading European scientific society involved in promoting research and education in hepatology. EASL attracts the foremost hepatology experts and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.

EASL’s main focus on education and research is delivered through numerous events and initiatives, including:

About The International Liver CongressTM 2014

The International Liver Congress™ 2014, the 49th annual meeting of the European Association for the study of the Liver, is being held at ExCel London from April 9 – 13, 2014. The congress annually attracts in excess of 9000 clinicians and scientists from around the world and provides an opportunity to hear the latest research, perspectives and treatments of liver disease from principal experts in the field.

For further information on the studies, or to request an interview, please do not hesitate to contact the EASL Press Office on:

Email: easlpressoffice@cohnwolfe.com

Helena Symeou

+44 7976 562 430

Courtney Lock

+44 7894 386 422

1. C.Dargel et al. T-CELL RE-DIRECTION AGAINST GLYPICAN-3 FOR IMMUNOTHERAPY OF HCC. Abstract presented at the International LiverCongressTM 2014

2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F.GLOBOCAN 2012 v1.0,Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet].Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr Accessed 11.03.14

3. Liver Cancer Mortality Statistics http://www.cancerresearchuk.org/cancer-info/cancerstats/types/liver/mortality/uk-liver-cancer-mortality-statistics Accessed 11.03.14

4. Statistics and Outlook for Liver Cancer http://cancerhelp.cancerresearchuk.org/type/liver-cancer/treatment/statistics-and-outlook-for-liver-cancer. Accessed 11.03.14